Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Conmed ( (CNMD) ) has provided an update.
On March 13, 2026, CONMED Corporation announced that Andrew Moller, 51, will be appointed Interim Principal Financial Officer effective March 15, 2026, following his prior roles as Vice President, Corporate Controller and Principal Accounting Officer since joining the company in early 2025. Moller, a certified public accountant with prior senior finance positions at Smith & Nephew and Stanley Black & Decker, assumes the interim finance leadership role without changes to his compensation, and the company confirmed there are no related-party transactions or family ties with the board, underscoring an emphasis on governance and continuity in its financial oversight.
The appointment highlights CONMED’s reliance on experienced internal talent to maintain financial stability and regulatory compliance during a leadership transition. Stakeholders are likely to view the move as a signal of operational continuity, given Moller’s extensive background in global finance roles and internal audit, as well as the company’s explicit disclosure of the absence of conflicts of interest.
The most recent analyst rating on (CNMD) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Conmed stock, see the CNMD Stock Forecast page.
Spark’s Take on CNMD Stock
According to Spark, TipRanks’ AI Analyst, CNMD is a Neutral.
The score is driven primarily by steady cash-flow strength but held back by volatile profitability and meaningful leverage. Technicals are only modestly supportive (better short-term, weaker long-term), while valuation appears demanding for a business facing near-term tariff and portfolio-transition headwinds despite constructive 2026 guidance.
To see Spark’s full report on CNMD stock, click here.
More about Conmed
CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment used in a range of clinical settings. The company focuses on orthopedics, minimally invasive procedures, and other hospital-based specialties, supplying products to healthcare providers worldwide in a competitive medtech market.
Average Trading Volume: 571,725
Technical Sentiment Signal: Sell
Current Market Cap: $1.13B
For a thorough assessment of CNMD stock, go to TipRanks’ Stock Analysis page.